14-day Premium Trial Subscription Try For FreeTry Free

Latest Data & Signals Issued

Signal Type Signal Value Data
Score -4.338 17 days ( 16.30 % )
Last Price $0.0615 4.24 %
High/ Low $0.0590 - $0.0640 10.08%
Chg 7 Days -5.38 % $0.0650 $0.0615
Chg 30 Days -14.11 % $0.0716 $0.0615
Chg 12 mos -65.83 % $0.180 $0.0615
Trend - 3 mos -13.97 % Width: 37.91 %
Trend - 12 mos -50.04 % Width: 1,659.92 %
Pred. range - 3 mos $0.0480 - $0.0662 -21.95 % - 7.64 %
Pred. range - 12 mos N/A - $0.103 -100.00 % - 67.27 %
Short MA avg 3 mos Buy May 02, 2024 - 2 days
Long MA avg 3 mos Buy Apr 09, 2024 - 19 days
Short/Long MA avg 3 mos Sell Apr 01, 2024 - 25 days
Short MA avg 12 mos Buy Apr 09, 2024 - 19 days
Long MA avg 12 mos Buy Apr 09, 2024 - 19 days
Short/Long MA avg 12 mos Sell Apr 15, 2024 - 15 days
Pivot Short Buy Apr 29, 2024 - 5 days
Bollinger Buy Apr 18, 2024 - 12 days
MACD Sell No Dates Stored For This Signal

Signals Effectiveness

Backtesting is not only a way to check stock signal accuracy, but also a tool to continually improvement. Data can be used for self adjustment as each stock has an individual behavior.

Accuracy and return is not the same. A stock signal may provide low statistical accuracy, but the signals may prove high return in average.

Sharp market dips or fundamental changes (earning reports, news updates etc), may force a short term reaction and disturb the signals (Signals may jump quickly from buy to sell, just to return to buy).

Stock Score

Buy Signals
Sell Signals

Bollinger Bands

Buy Signals
Sell Signals

MACD

Buy Signals
Sell Signals

Moving Average (7d)

Buy Signals
Sell Signals
Click to get the best stock tips daily for free!

About Aridis Pharmaceuticals Inc.

Aridis Pharmaceuticals. Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-32... ARDS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT